Compare BBCP & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | CCCC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 404.7M |
| IPO Year | 2017 | 2020 |
| Metric | BBCP | CCCC |
|---|---|---|
| Price | $10.53 | $3.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.25 | ★ $12.20 |
| AVG Volume (30 Days) | 289.5K | ★ 4.0M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $392,867,000.00 | $35,947,000.00 |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $5.56 | $1.69 |
| 52 Week High | $12.19 | $5.17 |
| Indicator | BBCP | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 43.11 |
| Support Level | $10.39 | $2.10 |
| Resistance Level | $12.08 | $3.89 |
| Average True Range (ATR) | 0.49 | 0.37 |
| MACD | -0.21 | -0.10 |
| Stochastic Oscillator | 7.78 | 16.47 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.